Cargando…

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab

Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was contin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mimori, Masahiro, Komatsu, Teppei, Maku, Takahiro, Mitsumura, Hidetaka, Iguchi, Yasuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975705/ https://www.ncbi.nlm.nih.gov/pubmed/35364770 http://dx.doi.org/10.1007/s10072-022-05922-2

Ejemplares similares

A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment
por: Alis, Ceren, et al.
Publicado: (2022)

The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis
por: Galassi, Giuliana
Publicado: (2022)

Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19
por: Scopelliti, Giuseppe, et al.
Publicado: (2020)

Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic
por: Ricciardi, Dario, et al.
Publicado: (2021)

An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis
por: Wang, H.Y., et al.
Publicado: (2023)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
por: Nóbrega, Paulo Ribeiro, et al.
Publicado: (2022)

COVID19 vaccine in myasthenia gravis patients: safety and possible predictors of disease exacerbation
por: Trinchillo, Assunta, et al.
Publicado: (2022)

COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined
por: Kim, Sohyeon, et al.
Publicado: (2023)

Reply to Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
por: Galassi, Giuliana, et al.
Publicado: (2022)

Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review
por: Rodrigues, Cleonisio Leite, et al.
Publicado: (2022)

Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series
por: Fanella, Gaia, et al.
Publicado: (2022)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
por: Muppidi, Srikanth, et al.
Publicado: (2019)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
por: Oyama, Munenori, et al.
Publicado: (2020)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report
por: Moschella, Phillip, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses
por: Howard, James F., et al.
Publicado: (2021)

Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab
por: Weidmayer, Sara L., et al.
Publicado: (2023)

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2020)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
por: Katyal, Nakul, et al.
Publicado: (2021)

Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series
por: Kang, Seung Ah, et al.
Publicado: (2022)

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
por: Murai, Hiroyuki, et al.
Publicado: (2021)

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
por: Vissing, John, et al.
Publicado: (2020)

Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
Publicado: (2021)

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
por: Vu, Tuan, et al.
Publicado: (2021)

Should I use steroid injections to treat shoulder pain during the COVID-19 pandemic?
por: Morgan, Catrin, et al.
Publicado: (2020)

Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report
por: Amano, Eiichiro, et al.
Publicado: (2019)

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study
por: Nowak, Richard J., et al.
Publicado: (2020)

Comparison of Clinical Manifestations between Patients with Ocular Myasthenia Gravis and Generalized Myasthenia Gravis
por: Roh, Hyun Seok, et al.
Publicado: (2011)

Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series
por: Datta, Sorabh, et al.
Publicado: (2020)

The Impact of Cerebral Microbleeds Presence on Outcome Following Minor Stroke Treated With Antiplatelet Therapy
por: Sakuta, Kenichi, et al.
Publicado: (2020)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
por: Waheed, Waqar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2c4f3q8df2d5322260j52mea52